Tri Acetyl Azacitidine
| Chemical Name | Tri Acetyl Azacitidine |
|---|---|
| Alternate Names | Azacitidine Impurities, Impurities of Azacitidine |
| CAT No. | CS-EO-00143 |
| CAS Registry# | 10302-78-0 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 370.31 g/mol |
| Mol. For. | C₁₄H₁₈N₄O₈ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Azacitidine |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CC(O[C@H]1[C@H](N(C=NC(N)=N2)C2=O)O[C@H](COC(C)=O)[C@H]1OC(C)=O)=O |
| Canonical Smiles | CC(=O)OCC1C(C(C(O1)N2C=NC(=NC2=O)N)OC(=O)C)OC(=O)C |
| InchIKey | OTQJVHISAFFLMA-DDHJBXDOSA-N |
| Inchl | InChI=1S/C14H18N4O8/c1-6(19)23-4-9-10(24-7(2)20)11(25-8(3)21)12(26-9)18-5-16-13(15)17-14(18)22/h5,9-12H,4H2,1-3H3,(H2,15,17,22)/t9-,10-,11-,12-/m1/s1 |
| IUPAC | [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)oxolan-2-yl]methyl acetate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Tri Acetyl Azacitidine, also known as TAAC, is a synthetic compound and a derivative of the chemotherapy drug Azacitidine. TAAC is used as an anti-cancer agent and is specifically used in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The chemical structure of TAAC is similar to Azacitidine, but with three acetyl groups added to the nitrogen atoms. This modification helps to increase the stability of the compound and also improves its bioavailability. TAAC works by inhibiting the activity of DNA methyltransferase enzymes, which causes the re-expression of silenced tumor suppressor genes and the suppression of cancer cell growth.
TAAC is administered via injection into the bloodstream and is typically given as a 30-minute infusion once a day for five consecutive days in a 28-day cycle. The dosage is determined by the patient's body weight and other factors such as kidney function.
In clinical trials, TAAC has shown promising results in the treatment of AML and MDS, with some patients achieving complete remission or significant improvement in their condition. However, like most chemotherapy drugs, TAAC can cause side effects such as low white blood cell count, fatigue, and increased risk of infection.
In conclusion, TAAC is a potent anti-cancer agent that shows great potential in the treatment of AML and MDS. Its chemical structure and mechanism of action make it a valuable addition to the arsenal of chemotherapy drugs available for these diseases. However, further research is needed to fully understand its effectiveness and potential side effects.
Get an Instant Quote
Related Compounds
Azacitidine Impurity C isomers 2 | Azacitidine Related compound C(Isomer-1) | Azacitidine Impurity 6 | Azacitidine Impurity C isomers | Azacitidine Impurity 16 | Azacitidine Impurity C isomers 2(Free Base) | Azacitidine Impurity 4 | Azacitidine Impurity 9 | Azacitidine impurity 48 | Beta-L-Ribofuranose | Azacitidine Impurity 7 | Azacitidine Related Compound B | Azacitidine Impurity 14 | Azacitidine N- Formyl Impurity | Azacitidine Impurity 23 | Azacitidine Impurity 1 | Azacitidine Impurity C isomers 3 | N-(Diaminoethylene)-N'-(β-D-ribofuranosyl)-carbamimidic Acid | Azacitidine Amine Isomer-4 | Azacitidine Related Compound -C Isomer -3 | Monoacyl Azacitidine | Azacitidine Impurity 24 | Azacitidine Impurity | Azacitidine Impurity C isomers 4 | Azacitidine Impurity 12 | Azacitidine Amine Impurity | Azacitidine Impurity 15 |